Orphan designation: motixafortide Treatment of patients undergoing haematopoietic stem cell transplantation, 12/01/2024 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 11 April 2024 - 11:13

Orphan designation: motixafortide Treatment of patients undergoing haematopoietic stem cell transplantation, 12/01/2024 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2885

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters